EP4536205A1 — Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

USPTO Abstract

The invention relates to soluble guanylate cyclase (sGC) activators, preferably (3 S )-3-(4-chloro-3- {[(2S,3 R )-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid (runcaciguat) and / or substituted pyrazolo piperidine carboxylic acids, preferably selected from the list consisting of 1-[1-{4-Chloro-4'-[4-(2-methylpropyl)piperazin-1-yl][1,1'-biphenyl]-2-yl}piperidin-3-yl]-5- (difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-[4-Chloro-4'-(4-isobutylpiperazin-1- yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid, 1-{3(R)-1-[4- Chloro-4'-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin-3-yl}-5-(difluoromethyl)-1H-pyrazole-4- carboxylic acid hydrochloride, 1-{3(R)-1-[4-Chloro-4'-(4-isobutylpiperazin-1-yl)[biphenyl]-2-yl]piperidin- 3-yl}-5-(difluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride hemihydrate or 1-[1-{4-chloro-4'- [4-(2-methylpropyl)piperazin-1-yl][1,1'-biphenyl]-2-yl}piperidin-3-yl]-5-(trifluoro-methyl)-1H- pyrazole-4-carboxylic acid hydrochloride (Enantiomer 1) for use in the treatment and/or prophylaxis of heart failure with preserved ejection fraction (HFpEF) in women and their use for preparing medicaments for the use in the treatment and/or prophylaxis of heart failure with preserved ejection fraction (HFpEF) in women.